Regarding MidSouth, I did not ask since I consider MidSouth a "non-event". They are a good size company but not large enough for the stock moving event that I am looking for.

I did ask about adding Agrastim (Beta Glucan) to pet foods with my special interest in Science Diet for cats. That is being worked on but to my education, I was told that getting Beta Glucan into pet food (dog and cat) is almost harder than getting an additive into human supplements. It is ironic to me that pet food is regulated as tight or tighter than human food/additives. Regardless, Purina is aware of Beta Glucan and could be a prospective customer. I was told that I could get Beta Glucan capsules for humans and add ten milligrams of high quality Beta Glucan for each cat to their cat food to get the health additive results.

For the situation of independent testing and analysis. As I have stated before, all in hindsight, it should not have come as a surprise to anyone but it did.

When BioAgra was being formed and the plant was being built, preliminary contacts were being made to a large number of prospective customers. The interest was and is very strong. That gave all of us the feeling that we would be able to sell all that we could produce, immediately.

When BioAgra began producing on never before seen quantities with top quality (80% viability or better), the prospective customers did what we should have expected but did not. They looked at the possibility that they would be changing their production model from anti-biotic to Agrastim and that would be measured in millions of dollars. So they did what any responsible company would do, they required BioAgra to validate Agrastim since it was a new Beta Glucan product, they required their own internal testing using Agrastim, they required cost analysis to justify their potentially huge change in feed focus.

Again, it should have been expected but wasn't. That has been a big discussion among all of us.

For me, I became more comfortable with BioAgra since the process of business development became more traditional than the idea of opening up the sales room and rushing out orders. As I said before, if we sold everything from the get-go, and our share price rose in reaction to that, to me it would have been irrational and I would have sold into that move. Today, the process is more rational.

Testing and analysis both independent and by prospective customers has been going on since BioAgra began production last April/May. Results of the testing has been very positive; mortality rates reduced for poultry and swine and shrimp, feed conversion rates increased (consumption versus waste), weight increased. Those are a few that I can remember at this moment.

So, for me, I treat BioAgra as a drug company, that has to go through phase trials before it can really take off. I do not treat Agrastim as a pharmaceutical (drug) because then we would have to go through the far more extensive three phase trials. That is why having GRAS (Generally regarded as Safe) designation was so important for Agrastim.

But we do need to go through the rigorous testing that multi million dollar orders require.

Again, it is frustrating to all of us that we did not anticipate this process but it is the reality. That is why we are at thirty cents at this time. The immediate revenues did not materialize.

But the past research on Beta Glucan of fifty years and the current testing and analysis of Agrastim is so positive that that is why a good number of us longs both keep sending checks to VytaCorp (our vehicle to support BioAgra) and nibbling in the open market.

As to Kristi's resignation of CFO being a non-event, well it would have been a huge event to me if she was not going to be available to get our filings done. That is a critical task in a publicly reporting company. But she is going to do our filings and I am relieved. Biggest change we will see is that Paul will have to sign the Sarbanes Oxley required forms instead of Kristi.

I am bullish on VytaCorp's future and BioAgra's future. That is why I am still in the stock and continue to fund Vyta's needs. And, with ExypnoTech's revenue growth being so strong (and I hope getting even stronger), I feel my original investment years ago is becoming vindicated. I look forward to seeing press releases regarding ExypnoTech's growth and this possible NCS license that was intimated in the past 10Q after six months (starting January 2007) of market testing.

Jeff, I know that many try to look at one thing or person to blame when their fortune fails. It is human nature. For me, I try to detach myself from the blame game and focus on how to reverse the lost fortune. That is why I have made the trips and many phone calls to try to understand what has happened and where we might be headed. And with that understanding, I remain bullish and hold long.

Kent